ライフサイエンスコーパス: prostate-specific membrane antigen

1 est degree of homology with the gene for the prostate specific membrane antigen.

2 novel radiolabeled small molecules targeting prostate-specific membrane antigen.

3 specificity for the extracellular domain of prostate-specific membrane antigen.

4 ig folylpoly-gamma-carboxypeptidase or human prostate-specific membrane antigen.

5 investigated whether and how (68)Ga-labeled prostate-specific membrane antigen 11 ((68)Ga-PSMA-11) P

6 his study was to assess the impact of (68)Ga-prostate-specific membrane antigen ((68)Ga-PSMA) PET/CT

7 heses, or pedicle screws) and (68)Ga-labeled prostate-specific membrane antigen ((68)Ga-PSMA) PET/CT

8 (68)Ga-labeled prostate-specific membrane antigen ((68)Ga-PSMA) PET/CT

9 us probe incorporating primer sequences from prostate-specific membrane antigen, a protein capable of

10 Prostate-specific membrane antigen, a type II integral m

11 onjugates with RNA aptamers that bind to the prostate-specific membrane antigen, a well-known prostat

12 cancer, antibodies to key antigens, such as prostate specific membrane antigen, along with metabolic

13 tate cancer (SyAM-Ps)-bind simultaneously to prostate-specific membrane antigen and Fc gamma receptor

14 )In-DOTAGA-(3-iodo-y)-f-k-Sub(KuE)) (PSMA is prostate-specific membrane antigen and I&T is imaging an

15 DNA is homologous to but distinct from human prostate-specific membrane antigen and rat brain N-acety

16 s a 751-amino acid polypeptide homologous to prostate-specific membrane antigen and rat brain N-acety

17 ptidase (NAALADase), and is identical to the prostate-specific membrane antigen and to the jejunal fo

18 es that target prostate-specific antigen and prostate-specific membrane antigen, and drugs that can b

19 against tumor-associated antigens, including prostate-specific membrane antigen, and elimination of p

20 vesicles displaying an aptamer that binds to prostate-specific membrane antigen, and loaded with surv

21 an spectroscopy, exogenous fluoroscopy using prostate-specific membrane antigen, and so on have led t

22 nal antibodies, antibody therapies targeting prostate-specific membrane antigen, and vaccines such as

23 PET and monoclonal antibody imaging with the prostate specific membrane antigen antibody (111)In-capr

24 d alpha-linked acidic dipeptidase, and human prostate-specific membrane antigen appear to represent v

25 An anti-prostate specific membrane antigen aptamer that has prev

26 Synchronous (68)Ga-labeled prostate-specific membrane antigen-avid malignancies wer

27 ke therapeutics in which a derivative of the prostate-specific membrane antigen-binding small molecul

28 those directed to glucose, choline, acetate, prostate-specific membrane antigen, bombesin, and amino

29 ion dependent upon T-cell recognition of the prostate-specific membrane antigen by a chimeric antigen

30 arkers, including prostate-specific antigen, prostate-specific membrane antigen, carcinoembryonic ant

31 dendritic cells exogenously pulsed with the prostate-specific membrane antigen-derived peptides, PSM

32 from the prostate-specific antigen (PSA) and prostate-specific membrane antigen gene regulatory regio

33 body that targets the external domain of the prostate-specific membrane antigen, has potential as an

34 state carcinoma tumors transduced with human prostate-specific membrane antigen (hPSMA) and a Renilla

35 dioimmunoscintigraphy (RIS) directed against prostate-specific membrane antigen in modifying postpros

36 3 lowered the kidney and liver uptake of the prostate-specific membrane antigen inhibitor each by a f

37 Recent evidence suggests that prostate-specific membrane antigen is also expressed in

38 therapy (RLT) with (177)Lu-PSMA-617 (PSMA is prostate-specific membrane antigen) is a novel targeted

39 a-linked acidic dipeptidase 2 (NAALAD2), and prostate-specific membrane antigen-like protein (PMSAL/G

40 esferrioxamine-IAB2M ((89)Zr-IAB2M), an anti-prostate-specific membrane antigen minibody, in patients

41 Another known gene coding for mouse prostate-specific membrane antigen (mPsma) is also highl

42 dose, 180 MBq; range, 126-189 MBq) targeting prostate-specific membrane antigen (n = 7) or human epid

43 Glutamate carboxypeptidase II (GCPII or prostate-specific membrane antigen or NAALADase) is an e

44 Prostate-specific membrane antigen PET tracers are in th

45 DOTATOC PET/CT (GEP NET), and (68)Ga-labeled prostate-specific membrane antigen PET/CT (PCA) but is s

46 ancies in patients undergoing (68)Ga-labeled prostate-specific membrane antigen PET/CT for prostate c

47 68)Ga(HBED-CC)] ((68)Ga-PSMA ligand; PSMA is prostate-specific membrane antigen) PET/CT in patients w

48 (68)Ga-PSMA (prostate-specific membrane antigen) PET/CT is increasing

49 Prostate-specific membrane antigen (PMSA) is an integral

50 eted RNAi agents that selectively sensitized prostate-specific membrane antigen-positive (PSMA-positi

51 te LNCaP epithelial cells, which express the prostate-specific membrane antigen protein (77-fold incr

52 ot enhanced in cells that do not express the prostate-specific membrane antigen protein.

53 -PCR for prostate-specific antigen (PSA) and prostate-specific membrane antigen (PSM) can detect circ

54 onal prostatic carcinoma marker known as the prostate-specific membrane antigen (PSM) possesses hydro

55 PCR) for prostate-specific antigen (PSA) and prostate-specific membrane antigen (PSM) to predict path

56 r proteins, prostate specific antigen (PSA), prostate specific membrane antigen (PSMA) and platelet f

57 I) microfluidic device that combines an anti-prostate specific membrane antigen (PSMA) antibody with

58 For prostate cancer, prostate specific membrane antigen (PSMA) has been ident

59 A series of phosphoramidate-based prostate specific membrane antigen (PSMA) inhibitors of

60 Prostate specific membrane antigen (PSMA) is a membrane-

61 Prostate specific membrane antigen (PSMA) is a validated

62 th small molecular entities, able to bind to prostate specific membrane antigen (PSMA), a transmembra

63 Prostate specific membrane antigen (PSMA), also known as

64 against prostate specific antigen (PSA) and prostate specific membrane antigen (PSMA), and then used

65 egy for the detection of a cancer biomarker, prostate specific membrane antigen (PSMA), at picomolar

66 which target the extracellular domain of the prostate specific membrane antigen (PSMA), for enhanced

67 to measure prostate specific antigen (PSA), prostate specific membrane antigen (PSMA), platelet fact

68 roteins are prostate specific antigen (PSA), prostate specific membrane antigen (PSMA), platelet fact

69 to aptamers that recognize the transmembrane prostate specific membrane antigen (PSMA), with cells se

70 ted for the detection of a tumor marker, the Prostate Specific Membrane Antigen (PSMA).

71 ytes expressing fusion receptors directed to prostate-specific membrane antigen (PSMA) and containing

72 and accessibility of (68)Ga tracers for the prostate-specific membrane antigen (PSMA) and other targ

73 ters of tumor cells using 213Bi-labeled anti-prostate-specific membrane antigen (PSMA) antibody, J591

74 Radioactive ligands for the prostate-specific membrane antigen (PSMA) are under deve

75 based low-molecular weight inhibitors of the prostate-specific membrane antigen (PSMA) are under inte

76 algorithms to predict peptide sequences from prostate-specific membrane antigen (PSMA) capable of sti

77 An alternatively spliced variant of prostate-specific membrane antigen (PSMA) designated PSM

78 bivalent antibody fragments, including anti-prostate-specific membrane antigen (PSMA) diabody (Db) a

79 for targeted immunoPET and quantification of prostate-specific membrane antigen (PSMA) expression in

80 Based on prostate-specific membrane antigen (PSMA) expression on

81 sferrioxamine B [DFO]-J591 for immuno-PET of prostate-specific membrane antigen (PSMA) expression was

82 ty of (68)Ga-labeled PET tracers against the prostate-specific membrane antigen (PSMA) for localizati

83 ed, (211)At-labeled small molecule targeting prostate-specific membrane antigen (PSMA) for the treatm

84 The prostate-specific membrane antigen (PSMA) has received i

85 recent years, several radioligands targeting prostate-specific membrane antigen (PSMA) have been clin

86 nt years, several radiotracers targeting the prostate-specific membrane antigen (PSMA) have been intr

87 Prostate cancer cells expressing prostate-specific membrane antigen (PSMA) have been targ

88 Small-molecule ligands specific for prostate-specific membrane antigen (PSMA) have the poten

89 range, 0.75-2.55 ng/mL) who underwent (68)Ga-prostate-specific membrane antigen (PSMA) HBED-CC PET/CT

90 sensitive immunoassay for quantitating serum prostate-specific membrane antigen (PSMA) hinders its cl

91 The anti-prostate-specific membrane antigen (PSMA) huJ591 antibod

92 anced prostate cancer and positive uptake in prostate-specific membrane antigen (PSMA) imaging were t

93 Prostate-specific antigen and prostate-specific membrane antigen (PSMA) immunohistoche

94 dioimmunoscintigraphy (RIS) directed against prostate-specific membrane antigen (PSMA) in influencing

95 dioimmunoscintigraphy (RIS) directed against prostate-specific membrane antigen (PSMA) in influencing

96 sis of the high and consistent expression of prostate-specific membrane antigen (PSMA) in metastatic

97 Radiolabeling of the prostate-specific membrane antigen (PSMA) inhibitor Glu-

98 ork aimed at the development of dual-labeled prostate-specific membrane antigen (PSMA) inhibitors der

99 In recent years, prostate-specific membrane antigen (PSMA) inhibitors wer

100 Prostate-specific membrane antigen (PSMA) is a cell surf

101 Prostate-specific membrane antigen (PSMA) is a promising

102 Prostate-specific membrane antigen (PSMA) is a promising

103 Prostate-specific membrane antigen (PSMA) is a trans-mem

104 Prostate-specific membrane antigen (PSMA) is a transmemb

105 Prostate-specific membrane antigen (PSMA) is a transmemb

106 Prostate-specific membrane antigen (PSMA) is a transmemb

107 Prostate-specific membrane antigen (PSMA) is a transmemb

108 Prostate-specific membrane antigen (PSMA) is a type 2 in

109 Prostate-specific membrane antigen (PSMA) is a type II i

110 Prostate-specific membrane antigen (PSMA) is a type II i

111 Prostate-specific membrane antigen (PSMA) is a well-char

112 Prostate-specific membrane antigen (PSMA) is a well-esta

113 Prostate-specific membrane antigen (PSMA) is a well-reco

114 The prostate-specific membrane antigen (PSMA) is an attracti

115 Prostate-specific membrane antigen (PSMA) is an excellen

116 Prostate-specific membrane antigen (PSMA) is expressed i

117 Prostate-specific membrane antigen (PSMA) is highly expr

118 Prostate-specific membrane antigen (PSMA) is highly expr

119 Prostate-specific membrane antigen (PSMA) is highly expr

120 Prostate-specific membrane antigen (PSMA) is highly expr

121 The prostate-specific membrane antigen (PSMA) is highly expr

122 The expression of prostate-specific membrane antigen (PSMA) is increased i

123 The prostate-specific membrane antigen (PSMA) is increasingl

124 The prostate-specific membrane antigen (PSMA) is increasingl

125 Because the prostate-specific membrane antigen (PSMA) is overexpress

126 Prostate-specific membrane antigen (PSMA) is overexpress

127 Prostate-specific membrane antigen (PSMA) is overexpress

128 on previous observations, we first show that prostate-specific membrane antigen (PSMA) is repressed b

129 The transmembrane peptidase prostate-specific membrane antigen (PSMA) is universally

130 Since prostate-specific membrane antigen (PSMA) is up-regulate

131 efficacy of the (177)Lu-labeled DOTAGA-based prostate-specific membrane antigen (PSMA) ligand (177)Lu

132 Therefore, we evaluated whether prostate-specific membrane antigen (PSMA) ligand PET/CT

133 lar imaging using PET/CT with (68)Ga-labeled prostate-specific membrane antigen (PSMA) ligands and mo

134 PET combined with CT and prostate-specific membrane antigen (PSMA) ligands has ga

135 Radiolabeled prostate-specific membrane antigen (PSMA) ligands repres

136 zed with the A10 aptamer, which binds to the prostate-specific membrane antigen (PSMA) on prostate ca

137 nd the A10 aptamer (Apt), which binds to the prostate-specific membrane antigen (PSMA) on the surface

138 Prostate-specific membrane antigen (PSMA) or folate hydr

139 rrelation of PSA changes with the results of prostate-specific membrane antigen (PSMA) PET follow-up

140 aluated the diagnostic value and accuracy of prostate-specific membrane antigen (PSMA) PET for the in

141 Prostate-specific membrane antigen (PSMA) PET/CT has a h

142 (68)Ga-prostate-specific membrane antigen (PSMA) PET/CT is a ne

143 (68)Ga-prostate-specific membrane antigen (PSMA) PET/CT is a pr

144 (177)Lu-prostate-specific membrane antigen (PSMA) radioligand th

145 er cells by constructing Pt(IV)-encapsulated prostate-specific membrane antigen (PSMA) targeted nanop

146 e high-affinity urea-based inhibitors of the prostate-specific membrane antigen (PSMA) that were synt

147 highly specific small molecule targeting the prostate-specific membrane antigen (PSMA) to deliver (12

148 There is increasing interest in PET/CT with prostate-specific membrane antigen (PSMA) tracers for im

149 fect of androgen receptor (AR) inhibition on prostate-specific membrane antigen (PSMA) uptake imaged

150 compounds labeled with (86)Y for imaging the prostate-specific membrane antigen (PSMA) using PET.

151 which a bivalent aptamer specifically binds prostate-specific membrane antigen (PSMA) via an antibod

152 The overexpression of the prostate-specific membrane antigen (PSMA) was exploited

153 A phage-derived peptide targeting the prostate-specific membrane antigen (PSMA) was geneticall

154 y construct targeting the external domain of prostate-specific membrane antigen (PSMA) was prepared a

155 Targeting the prostate-specific membrane antigen (PSMA) with (68)Ga-la

156 re that these materials are able to (1) bind prostate-specific membrane antigen (PSMA) with high affi

157 cles selectively bound either an antibody or prostate-specific membrane antigen (PSMA), a biomarker f

158 Prostate-specific membrane antigen (PSMA), a glutamyl pr

159 was designed for label-free immunosensing of prostate-specific membrane antigen (PSMA), a prostate ca

160 o PEDOT films for electrochemical sensing of prostate-specific membrane antigen (PSMA), a prostate ca

161 body (mAb) construct for targeted imaging of prostate-specific membrane antigen (PSMA), a prototypica

162 Prostate-specific membrane antigen (PSMA), a transmembra

163 Prostate-specific membrane antigen (PSMA), a type II tra

164 at recognize the extracellular domain of the prostate-specific membrane antigen (PSMA), a well charac

165 n peripheral blood T lymphocytes targeted to prostate-specific membrane antigen (PSMA), an antigen ex

166 We hypothesize that the prostate-specific membrane antigen (PSMA), an attractive

167 Prostate-specific membrane antigen (PSMA), initially def

168 radiofluorinated small-molecule inhibitor of prostate-specific membrane antigen (PSMA), N-[N-[(S)-1,3

169 tanis et al. report a new signaling role for prostate-specific membrane antigen (PSMA), providing a m

170 (68)Ga-labeled urea-based inhibitors of the prostate-specific membrane antigen (PSMA), such as (68)G

171 elopment of new imaging agents targeting the prostate-specific membrane antigen (PSMA), we have used

172 x 10(6)) (RM1), transduced to express human prostate-specific membrane antigen (PSMA), were injected

173 ad-to-head comparison between (68)Ga-labeled prostate-specific membrane antigen (PSMA)-11 and (18)F-f

174 was to estimate the effect of (68)Ga-labeled prostate-specific membrane antigen (PSMA)-11 PET on the

175 (68)Ga-prostate-specific membrane antigen (PSMA)-11 PET/CT repr

176 A library of new prostate-specific membrane antigen (PSMA)-binding ligand

177 tubule agent drug maytansinoid-1 directly to prostate-specific membrane antigen (PSMA)-expressing cel

178 rticle generator (225)Ac to selectively kill prostate-specific membrane antigen (PSMA)-expressing cel

179 Prostate-specific membrane antigen (PSMA)-ligand PET ima

180 tion-resistant prostate cancer patients with prostate-specific membrane antigen (PSMA)-positive tumor

181 The introduction of (18)F-labeled prostate-specific membrane antigen (PSMA)-targeted PET/C

182 Prostate-specific membrane antigen (PSMA)-targeted radio

183 PET imaging with the prostate-specific membrane antigen (PSMA)-targeted radio

184 -HBED-CC-a (68)Ga-conjugated ligand of human prostate-specific membrane antigen (PSMA)-to localize ca

185 xythiophene) (PEDOT) nanowires, that detects prostate-specific membrane antigen (PSMA).

186 ls overexpressing the known cancer biomarker prostate-specific membrane antigen (PSMA).

187 hemotherapeutic conjugate designed to target prostate-specific membrane antigen (PSMA).

188 dies targeting downstream effectors, such as prostate-specific membrane antigen (PSMA).

189 olecular-weight radiotracer that targets the prostate-specific membrane antigen (PSMA).

190 directed against an extracellular domain of prostate-specific membrane antigen (PSMA).

191 imaging and therapeutic agents targeting the prostate-specific membrane antigen (PSMA); these were am

192 (68)Ga-labeled prostate-specific membrane antigen (PSMA-11) PET/CT dete

193 xypeptidase II family, best characterized by prostate-specific membrane antigen (PSMA/NAALAD1).

194 Prostate-specific-membrane-antigen (PSMA) is a marker pr

195 n the neovasculature associated with tumors, prostate-specific membrane antigen represents an excelle

196 )Tc-MIP-1404), a small-molecule inhibitor of prostate-specific membrane antigen, shows high potential

197 conjugated to trastuzumab as well as to the prostate-specific membrane antigen-targeting compound RP

198 phosphoramidate peptidomimetic inhibitors of prostate-specific membrane antigen was determined by inh